Multilayered insights into the full spectrum of diffuse gliomas: a novel prognostic evaluation model
Authors:
Open Access
- 29 September 2025
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-20
Abstract
Background The intrinsic heterogeneity and invasiveness of diffuse gliomas complicate accurate prognosis. Existing approaches are largely constrained by subtype specificity or limited analytical dimensions. To address this gap, a multi- dimension–based prognostic framework encompassing the full glioma spectrum was developed, accompanied by an analysis of the associated immune microenvironment. Methods A total of 3,323 glioma samples from the SEER (n = 2181), CGGA (n = 807), and TCGA (n = 335) datasets were integrated. Differentially expressed genes were screened using the limma package, and a Lasso-Cox–based prognostic signature (Glioma-GDPM) was established. Clinical variables such as age, grade, and IDH mutation status were harmonized through propensity score matching to construct a multi-omics prognostic model (Glioma-GCDPM). GSEA, CIBERSORT-based immune infiltration analysis, and TIDE scoring were used to investigate the biological characteristics of different risk subgroups. Results Eleven key prognostic genes (such as PRAMEF2 and FADS1) and four clinical factors (age, tumor grade, IDH mutation, and 1p/19q codeletion) were identified. Glioma-GCDPM demonstrated favorable predictive ability in both the internal test cohort (AUC 0.81–0.86) and external validation sets (AUC 0.59–0.83). High-risk tumors exhibited greater invasiveness, with significant enrichment in cell cycle and proliferation-associated pathways. Additionally, a suppressed immune microenvironment was observed, reflected by elevated M2 macrophage infiltration and increased T cell dysfunction scores. Conclusion The multi-omics model established in this study enables precise stratification of prognostic risk in diffuse glioma patients and reveals immunosuppressive features in high-risk individuals, providing a new basis for personalized treatment strategies.Keywords
Funding Information
- Science and Technology Program of DeYang City (No.2023SZZ093)
- 2024 Sichuan Provincial Science and Technology Achievement Transfer and Transformation Guidance Program (No.2024ZHCG0018)
- 2025 Sichuan Provincial Key Research and Development Program (No. 25QYCX0359)
This publication has 64 references indexed in Scilit:
- Differential distribution of U6 (RNU6-1) expression in human carcinoma tissues demonstrates the requirement for caution in the internal control gene selection for microRNA quantificationInternational Journal of Molecular Medicine, 2015
- New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trialsNeuro-Oncology, 2013
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Oncogene AEG-1 Promotes Glioma-Induced Neurodegeneration by Increasing Glutamate ExcitotoxicityCancer Research, 2011
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3The Lancet Oncology, 2008
- Molecular targets of glioma invasionCellular and Molecular Life Sciences, 2007
- China Approves World's First Oncolytic Virus Therapy For Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- The WHO Classification of Tumors of the Nervous SystemJournal of Neuropathology & Experimental Neurology, 2002
- Brain TumorsNew England Journal of Medicine, 2001